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Biphasic metaplastic sarcomatoid carcinoma (MSC) of the breast accounts for <0.1% of all breast malignancies and has an uncertain progr
nostic significance.1,2 It is a form of metaplastic breast 
cancer with overt carcinomatous and sarcomatous 
features apparent with both light microscopy and imr
munohistochemical testing.2r4 MSC is usually associr
ated with a lower incidence of axilary nodal involver
ment than would be expected from similar sized typical 
breast adenocarcinomas. MSC has also been found to 
infrequently express hormone receptors with estrogen 
and or progesterone (ER/PR) positivity and there are 
limited data regarding HER2/neu overexpression in 
MSC.5 The diagnostic category includes squamous, adr
enosquamous and spindle cell/sarcomatoid carcinomas, 
as well as sorcalled carcinosarcoma, matrixrproducing 
carcinoma, and carcinoma with pseudosarcomatous 
metaplasia.6 Our case was a carcinosarcoma subtype. 
Carcinosarcoma is a generic term for biphasic neor
plasms having both malignant epithelium (carcinoma) 
and malignant stroma (sarcoma), with a 5ryear survival 
of 49% and 68%, respectively.3,7 Wargotz3 and Rayson8 
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biphasic metaplastic sarcomatoid carcinoma (msc) of the breast is rare and aggressive. patients with 
metaplastic breast carcinomas tend to have poor outcomes with a high risk of recurrence following pri-
mary surgery. most reports have shown that systemic therapy appears to be less effective. We report a case 
of a 42-year-old female who presented with a large (14 cm) cauliflower breast mass. biopsy revealed a 
poorly differentiated sarcoma. initially, neo-adjuvant concurrent chemoradiotherapy with a sarcoma regi-
men was prescribed, and the tumor regressed to a large ulcer. subsequent biopsy showed invasive ductal 
carcinoma (estrogen receptor, progesterone receptor stained weakly, 5%, her2:2+) and disappearance of 
the sarcomatous component. second-line neoadjuvant therapy was designed according to the histologic 
features of infiltrating ductal carcinoma, which led to nearly a complete response. a modified radical 
mastectomy of the right breast and axillary dissection was performed followed by monoclonal antibody 
(trastuzumab) therapy for 6 months due to the surgical specimen showing her2:3+. the treatment course 
went smoothly with a good response. the patient had no evidence of disease at 18 months.
also suggest that a metaplastic carcinoma prognosis is 
worse than that of typical breast carcinoma. As a conser
quence of the relative rarity and diagnostic heterogener
ity of these tumors, it has been difficult to determine 
optimal management for MSC. We describe a case of 
successfully treated biphasic metaplastic sarcomatoid 
carcinoma of the breast by evaluation of the immunor
histochemistry markers of the tumor cells.
CASE
A 42ryearrold female, who denied any systemic disease, 
came to our oncology outpatient department in May 
2008 with an initial presentation of a large, painless 
cauliflowerrlike mass (14 cm) arising from the right 
breast. She had noted the rapidly growing mass (from 
3 to 4 cm) for two months, but ignored it because it 
was painless at first. She was also embarrassed to see 
the doctor because of the conservative culture and a 
poor educational background. We were astonished 
with the large tumor, which occupied the whole right 
breast with a reddish margin and necrosis that bled 
easily upon touching (Figure 1A, B). There were fixed, 
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confluent axillary lymph nodes palpable during the 
physical examination. An incisional biopsy revealed 
a poorly differentiated neoplasm with sarcomatoid 
features. Immunohistochemical stains including cyr
tokeratin (CKAE1/AE3), vimentin, CD31, CD34, 
CD68,CD117, factor VIII, S100, desmin, epither
lial membrane antigen, HMBr45, leukocyte comr
mon antigen, synaptophycin and chromogranin were 
performed. All markers were essentially negative for 
tumor cells except for focally positive vimentin and 
factor VIII (Figure 2). The pathological features were 
described as poorly differentiated sarcoma and tumor 
cells were scattered individually in a patternrless strucr
ture, with pleomorphic nuclei and high mitotic activity. 
This mesenchymal tumor had a rich vascular network 
in the background, and the vascular networks were 
positive for CD31 and CD34 (negative in tumor cells), 
but the specimen was small and limited, so lymphovasr
cular permeation was not found. The CT scan showed 
a 14rcm lobulated heterogeneous hypodense mass over 
the right breast (Figure 3) with a 1.8 cm right axillary 
lymph node. The complete blood count and biochemr
istry were within normal limits and the tumor marker 
showed CEA of 1.4 ng/mL and CA153 of 8.1U/mL. 
The final diagnosis was poorly differentiated sarcoma, 
clinical stage IIIB (cT4N2Mx).
We treated the tumor as a sarcoma, with a cher
motherapy regimen of adriamycin, dacarbazine, and 
the antirVEGF agent, bevacizumab (Adriamycin 20 
mg 24rhour continuous infusion on day 1 and day 2, 
dacarbazine 400 mg on day 1 to day 4, with a 21rday 
cycle, bevacizumab 300 mg (5 mg/kg) every 2 weeks, 
for 4 courses and accompanied with hyperrfractional irr
radiation to the right breast tumor (120cGy times 44 
fractions). The tumor shrank dramatically in size and 
became an ulcerative wound. Rerbiopsy from the edge 
of the ulcerative wound showed residual invasive ducr
tal carcinoma (IDC) with ER of 5% (positive, weakly 
stained), PR of 5% (positive, weakly stained), Her2:2+, 
cytokeratin (CKAE1/AE3) and Ercadherin positive. 
The second course treatment was designed to treat IDC 
with a regimen of paclitaxel and gemcitabine (paclitaxel 
120 mg/m2 on day 1, gemcitabine 800 mg/m2 on day 
1 and day 8, with a 21rday cycle times 5 courses). A 
right modified radical mastectomy with axillary lymph 
node dissection was performed after a nearly complete 
response to preroperative therapy (Figure 1C) and the 
residual tumor revealed Her2:3+, ER 25%, PR 50%. As 
a result, of the tumor marker evaluation, trastuzumab 
was given for 6 months and then an antirestrogen agent 
(tamoxifen) for maintenance therapy. The patient was 
without evidence of disease at 18 months.
DISCUSSION
Biphasic metaplastic sarcomatoid carcinoma (MSC) is 
a rare disease with little information available to guide 
therapy.1,8 It is usually seen in women who are over 50 
years of age.3,4,7 MSC differs from typical adenocarcir
nomas in a number of pathologic and clinical variables. 
In the breast, the most popular theory regarding the 
histogenesis of the sarcomatous component is transforr
mation of myoepithelial cells.3,7,9,10 In support of this 
is the finding of a cuffrlike proliferation of neoplastic 
myoepithelial cells around residual breast ducts in some 
tumors.9,11 An alternative theory is that malignant epir
thelial cells undergo myofibroblastic metaplasia.9,12
It has also been observed that some tumors classir
fied as MSC behave in a manner similar to pure sarcor
mas, with an absence of regional lymph node involver
ment, an aggressive vascular pattern of metastasis, and 
a predication for pulmonary involvement.13 Hormone 
receptor expression in MSC is uncommon with a rer
ported estrogen/progesterone positivity in 0 to 17% 
of cases.3,4,14 Rayson indicated that MSC presenting 
with nodal involvement and hormone receptor expresr
sion is seen significantly less often.14,15 Axillary lymph 
node involvement is reported in 6%,3 26%,4 and 25r
30%16 of cases. Overexpression of HER2/neu was 4% 
(26 cases between 1971 and 2000 were retrieved from 
Canada).5,13 The risk of developing metastatic disease, 
however, is greater than expected based on historical 
comparisons to more common breast carcinoma varir
ants. Most published data on metastases of metaplasr
tic carcinoma have shown hematogenous (lung and 
bone) metastases rather than lymphatic spread.3,4,17 
Recurrence rates for nodernegative MSC have ranged 
from 35% to 62% within 2 to 5 years of initial diagnor
sis. This compares with a 17% to 20% risk of disease 
recurrence for invasive ductal carcinoma.15,18
Little has been reported on the systemic manager
ment of MSC. A previous series on the use of systemic 
therapy did not report obvious evidence of benefit for 
adjuvant chemotherapy or significant response rates 
to systemic chemotherapy and hormonal therapy for 
those with metastatic disease.5,8 The regimens used in 
MSC have included AC, AT (anthracycline/taxane), 
CMF (cyclophosphamide, methotrexate, flurouracil), 
CAF (cyclophosphamide, Adriamycin, fluorouracil) 
and rarely, tamoxifen in hormonerpositive patients. 
Hennessy et al2 reported that the outcome of CMFr
treated breast MSC patients was very poor, while par
tients treated with adjuvant anthracyclines seemed to 
do better, suggesting that CMF chemotherapy is less 
effective than anthracyclinerbased therapy in breast 
MSC. In the same study, a few cases (3 patients) treated 
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Figure 1A,B. The initial tumor, with diameter of 14cm, height 7 cm, necrotic changes and discharge.
Figure 1C. post neo-adjuvant chemotherapy, showing shrunken 
tumor. 
Figure 1D. 1-year post right modified mastectomy.
Figure 2A. The initial incisional biopsy showed poorly  ifferentiated 
sarcoma (200×). all sections of the breast tumor show poorly 
differentiated malignant cells arranged in sheets with rich 
vascular channels. The tumor cells were characterized by 
severe nuclear pleomorphism, with polygonal to spindle 
shape, abundant and pink cytoplasm with bizarre tumor cells. 
immunohistochemically, tumor cells were focally positive for 
vimentin and factor Viii only (tumor cells were positive for 
vimentin)
Figure 2B. The re-biopsy after neo-adjuvant chemotherapy 
showed residual tumor cells arranged in a ductal structure, 
and infiltrating the desmoplastic stroma. invasive carcinoma is 
present at the surgical margins (200×) (tumor cells are positive for 
cytokeratin (ae1/ae3).
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Figure 3A,B. The initial CT scan showed a large 14-cm lobulated hyterogeneous hypodense mass with necrosis in the right breast.
Figure 3C,D. CT scan after right modified masectomy in October 
2009.
with adjuvant sarcomartype chemotherapy were relapse 
free. A sarcomarlike chemotherapy regimen may be 
useful as a potential starting approach.
A study from MD Anderson Cancer Center sugr
gested that modified radical mastectomy should be conr
sidered for patients with breast MSC, particularly for 
patients with T2 and higherrstage disease.2 Certainly, 
the optimization of locorregional control is critical in 
these highrgrade patients. New radiation approaches 
and possibly concomitant radiorsensitizing agents are 
needed. The initial stage of the tumor had a strong asr
sociation with outcome, and the pathologic complete 
response rate to neoradjuvant chemotherapy was only 
10%.2However, the case we reported was a bulky tur
mor diagnosed with core needle biopsy. For the limr
ited volume of specimen, which showed sarcoma only 
in the beginning, the carcinoma may be masked until 
the rerbiopsy is performed after neoradjuvant therapy. 
This case of biphasic breast metaplastic sarcomatoid 
carcinomas was eventually treated successfully with a 
sarcoma or invasive ductal cancer regimen and then 
antirHER2 (trastuzumab). A long followrup is necr
essary since five other large series have found similar 
poor outcomes with reported diseaserfree survival 
rates of 35% to 62% at median followrup intervals of 
2 to 5.4 years.3,4,10,14
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